XOMA XOMA Royalty Corp.
USHealthcareAs of 2026-07-10 16:00
Why XOMA matters now
XOMA Royalty Corp. (XOMA) is a US stock in Healthcare. The latest InvestLog snapshot shows $44.22 with -1.29% on the session and $554.6M in market capitalization; recent performance reads 1-month +0.84% and YTD +57.54%.
The latest financial table shown here is Q1 2026, with revenue of $12.3M, net income of $4.5M, and EPS of $0.17. Investors can compare that operating picture with valuation signals such as P/E 14.00 and FCF yield 1.3%.
The latest indexable market news headline is "XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $44.50; recent insider activity includes Kosacz Barbara filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
14.00
PEG
0.04
P/B
4.41
P/S
14.50
EV/EBITDA
11.08
DCF Value
$-50.89
FCF Yield
1.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.3%
Operating Margin
13.7%
Net Margin
87.0%
ROE
30.2%
ROA
11.6%
ROIC
1.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $12.3M | $4.5M | $0.17 |
| Q4 2025 | $1.4M | $6.1M | $0.26 |
| FY 2025 | $52.1M | $31.7M | $1.46 |
| Q3 2025 | $9.4M | $14.1M | $0.70 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$44.50
Target (Median)
$44.50
Target Range
$39.00 - $50.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.87
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.